NeuroKaire
PrivateLast Round
VC Round
Dec 17, 2024
Total Funding Raised
$29.89M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
NeuroKaire operates in Healthcare & Life Sciences and is based in Kearny, New Jersey. Its latest recorded funding round was a VC Round in December 2024.
NeuroKaire is a biotechnology company that provides a personalized medical testing tool to help physicians find the best drug therapy for patients with psychiatric and neurological conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Mental Health, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroKaire Comparables
Compare NeuroKaire with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HMNC Brain Health | 78% | |
| Herophilus | 77% | |
| Cerevance | 77% |
For institutional investors. Book with your work email.
NeuroKaire Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 17, 2024 | ||||
| Grant | Jul 26, 2022 | ||||
| Series A | Sep 30, 2021 | ||||
| Seed | May 1, 2019 | ||||
| Accelerator | Nov 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeuroKaire Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| Israel Innovation Authority | Seed |
| MassChallenge Israel | Accelerator |
| Meron Capital | Series A, Seed, VC Round |
| Jumpspeed Ventures | Series A, Seed, VC Round |
| Sapir Venture Partners | Series A, Seed, Accelerator |
| GreyBird Ventures | Series A, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 25, 2026
Grew 19% QoQ, from 37 to 44 employees.
- Nov 9, 2025
Monthly visitors grew 77% MoM, reaching 2.5K.
For institutional investors. Book with your work email.
NeuroKaire Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuroKaire's valuation, stock price, and market status.
Is NeuroKaire a public or private company?
NeuroKaire is a private company.
What is the current stock price of NeuroKaire?
NeuroKaire is a private company, so its shares have no public market price. Caplight tracks NeuroKaire's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuroKaire worth (valuation)?
Valuation information for NeuroKaire is not publicly available.
Can I buy NeuroKaire stock?
NeuroKaire shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuroKaire's last funding round?
NeuroKaire's most recent funding round was VC Round on December 17, 2024.
Who are the main investors in NeuroKaire?
Key investors in NeuroKaire include GreyBird Ventures.
Will NeuroKaire IPO soon?
No public IPO plans have been announced for NeuroKaire.
How can I track NeuroKaire secondary market activity?
Caplight tracks bids, offers, and trades in NeuroKaire's shares on secondary markets.